Learn About Chronic Graft Versus Host Disease (cGvHD)
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Emory Winship Cancer Institute
Edmund Waller is a Hematologist Oncology provider in Atlanta, Georgia. Dr. Waller has been practicing medicine for over 41 years and is rated as an Elite provider by MediFind in the treatment of Chronic Graft Versus Host Disease (cGvHD). His top areas of expertise are Graft Versus Host Disease (GvHD), Chronic Graft Versus Host Disease (cGvHD), Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), and Bone Marrow Transplant.
Emory Winship Cancer Institute
Amelia Langston is a Hematologist Oncology provider in Atlanta, Georgia. Dr. Langston has been practicing medicine for over 42 years and is rated as an Elite provider by MediFind in the treatment of Chronic Graft Versus Host Disease (cGvHD). Her top areas of expertise are Graft Versus Host Disease (GvHD), Chronic Graft Versus Host Disease (cGvHD), Aplastic Anemia, Bone Marrow Transplant, and Bone Marrow Aspiration.
Duke Adult Blood And Marrow Transplant Clinic
Nelson Chao is an Oncologist and a Transplant Surgeon in Durham, North Carolina. Dr. Chao is rated as a Distinguished provider by MediFind in the treatment of Chronic Graft Versus Host Disease (cGvHD). His top areas of expertise are Chronic Graft Versus Host Disease (cGvHD), Multiple Myeloma, Acute Myeloid Leukemia (AML), Bone Marrow Transplant, and Bone Graft. Dr. Chao is currently accepting new patients.
Summary: This study will be conducted to compare Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy.
Background: * Chronic graft-versus-host disease (cGVHD) is a multi-organ alloimmune and autoimmune disorder that occurs following allogeneic hematopoietic stem cell transplantation (alloHSCT). It is characterized by immune dysregulation, immunodeficiency, impaired organ function, and decreased survival. * Each year about 8000 patients receive allogeneic hematopoietic stem cell transplant (alloHSCT) in North A...